Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets remain buoyant
Wed, 22 Jan 01:30 pm

Indian share markets continued to trade higher in the post-noon trading session. Barring FMCG and capital goods, all the sectoral indices are trading in the green with pharma, metal and power stocks being the biggest gainers.

BSE-Sensex is up 58 points and NSE-Nifty is trading 14 points up. BSE Mid Cap is trading 0.4% up and BSE Small Cap index is trading up by 0.3%. The rupee is trading at 61.9 to the US dollar.

Majority of the FMCG stocks are trading in the green with Jyothy Consumer and Emami being among major gainers and Hindustan Unilever and Dabur being the biggest losers. As per a leading financial daily, Colgate announced its results for the quarter ended December 2013. The company reported a 14% topline growth. However, growth in operating profit remained almost flat due to over 20% jump in each of the ad-spends and other expenses reported during the quarter that offset a 16% cut in staff costs. The operating margin contracted by 2.2% to 16.9%. At the net level, margins reduced by a mere 1.5% to 12.7% aided by 38% increase in other income earned for the quarter. The company has declared a second interim dividend of Rs 9 per share in addition to a first interim dividend of Rs 9 per share declared in November 2013. Colgate stock is trading up 0.4%.

Barring Panacea Biotech, almost all the Indian pharma stocks are trading firm with Torrent Pharma and Natco Pharma leading the pack of gainers. As per a leading business daily, Indian drug companies get a breather after the United States Food & Drug Administration (USFDA) relaxed inhaler norms. USFDA has eased guidelines for cheap generic inhaler alternatives to GlaxoSmithKline's blockbuster respiratory drug, Advair. The drug is used as inhaled medicine for asthma and chronic obstructive pulmonary disorder. The relaxation in the norm would help pharma companies skip long and expensive human tests. Advair is the world's 3rd best selling drug with a turnover of USD 8 bn during previous year out of which US alone accounts for USD 5 bn a year. Indian pharma giants like Sun Pharma, Lupin and Cipla are already preparing to launch their generic inhaler alternatives in the US markets. For instance, Glenmark has already launched its Advair generic for the emerging markets. The companies are expediting their processes to seek approvals in the US market. The opportunity for the inhaler segment is significant with the US market alone being pegged at about USD 23 bn.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets remain buoyant". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.